Premium
Blinatumomab following haematopoietic stem cell transplantation – a novel approach for the treatment of acute lymphoblastic leukaemia in infants
Author(s) -
Popov Alexander,
Fominikh Veronika,
Mikhailova Ekaterina,
Shelikhova Larisa,
Tsaur Grigory,
Abugova Yulia,
Zerkalenkova Elena,
Olshanskaya Yulia,
Balashov Dmitry,
Novichkova Galina,
Maschan Alexey,
Miakova Natalia
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17466
Subject(s) - blinatumomab , haematopoiesis , stem cell , transplantation , medicine , hematology , immunology , hematopoietic stem cell transplantation , transplantation chimera , oncology , hematopoietic cell , lymphoblastic leukemia , leukemia , biology , genetics
Summary Blinatumomab with subsequent haematopoietic stem cell transplantation was applied in 13 infants with acute lymphoblastic leukaemia (ALL). Eight patients were treated in first remission due to slow clearance of minimal residual disease (MRD); one for MRD‐reappearance after long MRD negativity, one for primary refractory disease and three during relapse treatment. In slow MRD responders, complete MRD response was achieved prior to transplantation, with an 18‐month event‐free survival of 75%. In contrast, only one of five patients with relapsed/refractory ALL is still in complete remission. These data provide a basis for future studies of immunotherapy in very high‐risk infant ALL.